ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Tetraphase Pharmaceuticals Inc.
2.20
0.0000
成交量:
- -
成交額:
- -
市值:
1,597.91萬
市盈率:
-0.17
高:
2.20
開:
2.20
低:
2.20
收:
2.20
52周最高:
8.60
52周最低:
0.5600
股本:
726.32萬
流通股本:
503.36萬
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
-13.3067
每股收益(LYR):
-22.8513
淨資產收益率:
-138.80%
總資產收益率:
-51.46%
市淨率:
0.58
市盈率(LYR):
-0.10
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字:
Tetraphase Pharmaceuticals Inc.
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
http://www.tphase.com
郵編:
- -
電話:
- -
傳真:
- -
簡介:
Tetraphase Pharmaceuticals, Inc.依據特拉華州法律於2006年7月7日成立,是一家臨床階段的生物製藥公司,利用其專有的化學技術為嚴重的、威脅生命的、有多種抗藥性的感染病的治療創造新型的抗生素。公司領先的藥品替代物eravacycline是一種完全的合成四環素衍生物,將作為首要的偏方單一治療法發展成一種廣泛的靜脈注射和口服的抗生素,用於治療抗多種藥物感染病的治療,包括革蘭氏陰性感染病。公司最近為患有複雜腹內感染病(cIAI)患者採用靜脈內給藥的方式成功完成了eravacycline階段二的臨床試驗,目前正在進行關鍵性的eravacycline階段三測試。公司期望完成兩項全球性的eravacycline階段三臨床試驗,一項是對cIAI的治療試驗,另一項是對複雜尿路感染餅(cUTI)的治療試驗。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易,超低佣金,新手也能轻松开启投资。在老虎证券, 1 美元起投资美股,24/5 无时差交易美股,澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TTPH/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"TTPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTPH\",,,,,undefined,":{"symbol":"TTPH","market":"US","secType":"STK","nameCN":"Tetraphase Pharmaceuticals Inc.","latestPrice":2.2,"timestamp":1595966400000,"preClose":2.2,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":5033625,"shares":7263236,"eps":-13.306672,"marketStatus":"退市","change":0,"latestTime":"07-28 16:00:00 EDT","open":2.2,"high":2.2,"low":2.2,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.306672,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773216000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1363752000000,"exchange":"NASDAQ","adjPreClose":2.2,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTPH\",,,,,undefined,":{"symbol":"TTPH","floatShares":5033625,"roa":"-51.46%","roe":"-138.80%","lyrEps":-22.85132,"shares":7263236,"dividePrice":0,"high":2.2,"amplitude":0,"preClose":2.2,"low":2.2,"week52Low":0.56,"pbRate":"0.58","week52High":8.6,"institutionHeld":0,"latestPrice":2.2,"eps":-13.306672,"divideRate":0,"volume":0,"delay":0,"ttmEps":-13.306672,"open":2.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-07","symbol":"TTPH","fiscalQuarterEnding":"2020/03","expectedEps":-1.63,"name":null,"time":"","type":"earning","dateTimestamp":1588824000000,"reportTimeType":"","actualEps":-1.31},{"market":"US","date":"2020-03-12","symbol":"TTPH","fiscalQuarterEnding":"2019/12","expectedEps":-5.68,"name":null,"time":"","type":"earning","dateTimestamp":1583985600000,"reportTimeType":"","actualEps":null},{"date":"2019-11-12","symbol":"TTPH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-6.27,"defaultRemindTime":1573592400000,"name":null,"time":"盤後","dateTimestamp":1573534800000,"actualEps":null},{"market":"US","date":"2019-09-27","symbol":"TTPH","type":"split","dateTimestamp":1569556800000,"forFactor":20,"toFactor":1,"ratio":20},{"date":"2019-08-08","symbol":"TTPH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.38,"defaultRemindTime":1565294400000,"name":null,"time":"盤後","dateTimestamp":1565236800000,"actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTPH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTPH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTPH","date":"2020-07-28","current":-0.165331,"percent":0.148148,"low":-0.322562,"twenty":-0.24552,"median":-0.163297,"eighty":-0.111312,"high":-0.068361,"avg":-0.171046,"sd":0.066471,"marketCap":16652545},"quantilePoints":[],"updateTime":1773204972123},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.tphase.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Tetraphase Pharmaceuticals, Inc.依據特拉華州法律於2006年7月7日成立,是一家臨床階段的生物製藥公司,利用其專有的化學技術為嚴重的、威脅生命的、有多種抗藥性的感染病的治療創造新型的抗生素。公司領先的藥品替代物eravacycline是一種完全的合成四環素衍生物,將作為首要的偏方單一治療法發展成一種廣泛的靜脈注射和口服的抗生素,用於治療抗多種藥物感染病的治療,包括革蘭氏陰性感染病。公司最近為患有複雜腹內感染病(cIAI)患者採用靜脈內給藥的方式成功完成了eravacycline階段二的臨床試驗,目前正在進行關鍵性的eravacycline階段三測試。公司期望完成兩項全球性的eravacycline階段三臨床試驗,一項是對cIAI的治療試驗,另一項是對複雜尿路感染餅(cUTI)的治療試驗。","exchange":"NASDAQ","name":"Tetraphase Pharmaceuticals Inc.","nameEN":"Tetraphase Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TTPH\",market:\"US\",,,undefined,":null}}